Patiromer

Eli Lilly's Alzheimer's drug Kisunla (donanemab) gains approval in Japan, following US FDA approval in July. Kisunla targets early symptomatic Alzheimer's, showing significant cognitive decline reduction in the TRAILBLAZER-ALZ 2 study. Japan's aging population makes it a key market, with dementia cases expected to reach 5 million by 2030, mostly Alzheimer's. Lilly emphasizes Kisunla's cost-effectiveness due to fixed treatment duration.

ESC/ESH guidelines for hypertension management, global epidemiology, health burden, and effective interventions for elevated blood pressure and hypertension, blood pressure lowering for prevention of cardiovascular disease and death, worldwide trends in hypertension prevalence and progress in treatment and control, global effect of modifiable risk factors on cardiovascular disease and mortality, dietary factors associated with hypertension, nutritional factors in the control of blood pressure and hypertension, WHO global report on sodium intake reduction, effects on blood pressure of reduced dietary sodium and the DASH diet, salt sensitivity of blood pressure, definitions and characteristics of sodium sensitivity and blood pressure resistance, effects of comprehensive lifestyle modification on blood pressure control, sodium reduction and weight loss in the treatment of hypertension in older persons, effect of dietary sodium on blood pressure, salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities, effect of salt substitution on cardiovascular events and death, effect of a salt substitute on incidence of hypertension and hypotension among normotensive adults, European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement, hypertension management in patients with cardiovascular comorbidities, ESH guidelines for the management of arterial hypertension, Force on clinical practice guidelines, sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings, effects of cuff size on the accuracy of blood pressure readings, relationship between clinic and ambulatory blood pressure and mortality, office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes, antisense inhibition of angiotensinogen with IONIS-AGT-LRx, Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension, counteracting angiotensinogen small-interfering RNA-mediated antihypertensive effects with reversir, effects of aldosterone on the vasculature, aldosterone and the cardiovascular system: genomic and nongenomic effects, methods article for a study protocol: study design and baseline characteristics for aldosterone synthase inhibition in chronic kidney disease, effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension, phase 2 trial of baxdrostat for treatment-resistant hypertension, CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, LY3045697: results from two randomized clinical trials of a novel inhibitor of aldosterone synthase, aldosterone synthase inhibition with Lorundrostat for uncontrolled hypertension, resistant hypertension: detection, evaluation, and management, prediction and management of hyperkalemia across the spectrum of chronic kidney disease, patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease, effect of KBP-5074 on blood pressure in advanced chronic kidney disease, cardiovascular events with finerenone in kidney disease and type 2 diabetes, effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes, canagliflozin and cardiovascular and renal events in type 2 diabetes, reductions in mean 24‐hour ambulatory blood pressure after 6‐week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension, blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease, the relationship between SGLT2 and systemic blood pressure regulation, efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension, obesity-induced hypertension, metabolic surgery for hypertension in patients with obesity, hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled, effects of gastric bypass surgery in patients with hypertension, effects of bariatric surgery in obese patients with hypertension, three-year outcomes of bariatric surgery in patients with obesity and hypertension, randomized trial of effect of bariatric surgery on blood pressure after 5 years, recommendations for blood pressure measurement in humans and experimental animals.